Can Prebiotics Help Protect Against Immunotherapy-Induced Colitis?

Studies suggest the gut microbiome can influence immunotherapy side effects. Butyrate emerges as an intriguing candidate against inflammation in the colon.

9:07 AM

Author | Ian Demsky

colorful cells in intestine with yellow badge bottom right corner saying lab note in blue
Getty Images

Prebiotics are an intriguing potential approach to curbing some of the severe side effects that life-saving immunotherapy treatments can wreak on the gut, according to an analysis of recent studies and clinical trials by researchers at the University of Michigan Rogel Cancer Center.

Rather than trying to introduce beneficial strains of bacteria directly into a patient's digestive tract — via fecal transplant, enema or probiotic supplements, each of which have drawbacks — evidence points to prebiotics as a potentially safe and effective strategy. This would mean giving patients foods that are known to stimulate the growth of certain bacteria that can, in turn, produce larger amounts of protective metabolites.

"There are several advantages to a prebiotic approach," says hematology/oncology fellow Amy Chang, M.D., the lead author of a recent article on the topic in Trends in Cancer. "Compared to other methods, they're easy to administer, safe and inexpensive. One study showed that oat bran, for example, increased production of a metabolite called butyrate and resulted in improved symptoms for patients with bowel ailments similar to those seen in patients receiving immunotherapy."

Immune checkpoint inhibitors have emerged as a significant advance against a variety of cancer types. But severe side effects — especially inflammation and organ damage caused by the amplification of the body's immune response — can force treatments to be discontinued.

The researchers' review of existing studies and clinical trials raised the possibility that butyrate-promoting prebiotics may help reduce immunotherapy-induced inflammation in the colon, and might even be able to improve the effectiveness of the therapy by increasing patients' tolerance to it through the promotion of beneficial microbes.

The article builds on other research at U-M, including an ongoing clinical trial to explore whether butyrate can help reduce rates of acute graft-versus-host-disease of the intestine, a serious complication of bone marrow transplantation.

"The evidence that exists is compelling, and we believe well-designed clinical trials could help us evaluate the potential of prebiotics to improve outcomes for cancer patients treated with immune checkpoint inhibitors," says Chang, who worked closely with senior study authors Christopher Lao, M.D., M.P.H. and Muneesh Tewari, M.D., Ph.D., both of whom are members of the Rogel Cancer Center.

The researchers are preparing to open a pilot clinical trial to test a prebiotic dietary supplement in patients receiving immunotherapy.

Paper cited: "Targeting the Gut Microbiome to Mitigate Immunotherapy-Induced Colitis in Cancer," Trends in Cancer. DOI: 10.1016/j.trecan.2021.02.005


More Articles About: Lab Notes Vitamin Supplements Cancer Research Cancer: Cancer Types Clinical Trials All Research Topics Crohn's and Colitis Nutrition
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of healthcare news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories Jianping Fu, Ph.D., Professor of Mechanical Engineering at the University of Michigan and the corresponding author of the paper being published at Nature discusses his team’s work in their lab with Jeyoon Bok, Ph.D. candidate at the Department of Mechanical Engineering.
Health Lab
Human stem cells coaxed to mimic the very early central nervous system
The first organized stem cell culture model that resembles all three sections of the embryonic brain and spinal cord could shed light on developmental brain diseases
Health care provider with stethoscope holds patient's hand
Health Lab
Combatting prostate cancer stigma
Prostate cancer is highly treatable and over 98% of men survive 10 years if the cancer is diagnosed and treated early.
Woman in pink shirt lifts kettleball in an outdoor exercise class
Health Lab
How to make cancer prevention more equitable
Expert explains six behavioral risk factors for cancer and why current programs don’t always meet the needs of people from racially and ethnically minoritized groups and other vulnerable populations.
Portrait of Max Wicha, founding director of Rogel Cancer Center
Health Lab
‘We might for the first time really be thinking of cures of cancer’
Founding Rogel Cancer Center Director reflects on how cancer evolved from ‘the least scientific discipline’ to a shining example of how basic research discoveries can change clinical care.
Animated illustration of weight loss drug container with a heart
Health Lab
Should heart patients consider taking weight loss medications?
Cardiologist shares how weight loss medications may impact cardiovascular health.
Minding Memory with a microphone and a shadow of a microphone on a blue background
Minding Memory
Racial Disparities in Alzheimer’s Disease and Related Dementias
In this episode of Minding Memory, Matt & Donovan speak with Dr. Lisa Barnes, the Alla V. and Solomon Jesmer Professor of Gerontology and Geriatric Medicine, Department of Neurological Sciences and Associate-Director of the Rush Alzheimer’s Disease Center at Rush University. Dr. Barnes talks with Matt & Donovan about racial disparities in Alzheimer’s disease dementia and several obstacles that have impeded our understanding of race and dementia.